A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

September 3, 2019

Primary Completion Date

April 19, 2024

Study Completion Date

April 19, 2024

Conditions
Metastatic CancerSolid TumorsAdvanced Cancer
Interventions
BIOLOGICAL

ASP9801

Administered by intratumoral injection

COMBINATION_PRODUCT

Pembrolizumab

Administered by Intravenous Infusion

Trial Locations (17)

14263

Roswell Park Cancer Institute - Medical Oncology, Buffalo

15260

University of Pittsburgh Medical Center, Pittsburgh

19111

Fox Chase Cancer Center, Philadelphia

21201

University of Maryland Medical Center, Baltimore

22903

UVA Cancer Center, Charlottesville

23298

VCU Massey Cancer Center, Richmond

35233

University of Alabama at Birmingham, Birmingham

40241

Norton Cancer Institute, Louisville

40536

University of Kentucky, Markey Cancer Center, Lexington

48202

Henry Ford Hospital, Detroit

55455

University of Minnesota, Minneapolis

60637

The University of Chicago Medical Center, Chicago

68130

Nebraska Methodist Hospital, Omaha

75251

Mary Crowley Cancer Research Center, Dallas

77030

The University of Texas - MD Anderson Cancer Center, Houston

85719

University of Arizona - Arizona Cancer Center, Tucson

90025

The Angeles Clinic and Research Institute, Los Angeles

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT03954067 - A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter